Inhibition of p38 mitogen-activated protein kinase potentiates the apoptotic effect of berberine/tumor necrosis factor-related apoptosis-inducing ligand combination therapy

Refaat,Alaa; Abdelhamed,Sherif; Saiki,Ikuo; Sakurai,Hiroaki

doi:10.3892/ol.2015.3494

Inhibition of p38 mitogen-activated protein kinase potentiates the apoptotic effect of berberine/tumor necrosis factor-related apoptosis-inducing ligand combination therapy

Authors:
- Alaa Refaat
- Sherif Abdelhamed
- Ikuo Saiki
- Hiroaki Sakurai
View Affiliations

Affiliations: Division of Pathogenic Biochemistry, Department of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama 930‑0194, Japan, Division of Cancer Cell Biology, Graduate School of Pharmaceutical Sciences, University of Toyama, Toyama 930‑0194, Japan
Published online on: July 15, 2015 https://doi.org/10.3892/ol.2015.3494
Pages: 1907-1911

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It was previously reported that berberine (BBR) and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) exhibited a synergistic apoptotic effect on triple negative breast cancer (TNBC) cells. In addition, the BBR/TRAIL combination treatment sensitized TRAIL‑resistant TNBC cells to TRAIL. The aim of the present study was to investigate a novel pathway for enhancing the apoptotic effect of BBR/TRAIL through mitogen‑activated protein kinases (MAPKs). Selective inhibitors and small interfering RNAs were utilized to understand the role of p38 MAPK in this pathway. The results demonstrated that p38 MAPK was activated in response to the combination therapy in TRAIL‑resistant TNBC cells. In addition, it was revealed that the inhibition of p38 enhanced apoptosis in epidermal growth factor receptor (EGFR)‑overexpressing MDA‑MB‑468 TNBC cells and EGFR‑mutant PC‑9 non‑small‑cell lung carcinoma cells, which was associated with the downregulation of EGFR serine phosphorylation. Viability assays for these two cell lines also confirmed the significant reduction of cell viability following p38 inhibition in BBR/TRAIL‑treated cells. In conclusion, the present study provided novel evidence for the role of p38 in suppressing BBR/TRAIL-mediated apoptosis and its association with EGFR, which may explain the mechanism of treatment resistance in certain types of cancer.

View Figures

View References

1	Refaat A, Abdelhamed S, Yagita H, Inoue H, Yokoyama S, Hayakawa Y and Saiki I: Berberine enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast cancer. Oncol Lett. 6:840–844. 2013.PubMed/NCBI
2	Zhang Y, Li X, Zhang Q, Li J, Ju J, Du N, Liu X, Chen X, Cheng F, Yang L, et al: Berberine hydrochloride prevents postsurgery intestinal adhesion and inflammation in rats. J Pharmacol Exp Ther. 349:417–426. 2014. View Article : Google Scholar : PubMed/NCBI
3	Sakurai H: Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci. 33:522–530. 2012. View Article : Google Scholar : PubMed/NCBI
4	Keane MM, Ettenberg SA, Nau MM, Russell EK and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59:734–741. 1999.PubMed/NCBI
5	Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, et al: Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol. 25:1390–1395. 2007. View Article : Google Scholar : PubMed/NCBI
6	Dyer MJ, MacFarlane M and Cohen GM: Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol. 25:4505–4506. 2007. View Article : Google Scholar : PubMed/NCBI
7	Abdelhamed S, Yokoyama S, Refaat A, Ogura K, Yagita H, Awale S and Saiki I: Piperine enhances the efficacy of TRAIL-based therapy for triple-negative breast cancer cells. Anticancer Res. 34:1893–1899. 2014.PubMed/NCBI
8	Refaat A, Abd-Rabou A and Reda A: TRAIL combinations: The new ‘trail’ for cancer therapy (Review). Oncol Lett. 7:1327–1332. 2014.PubMed/NCBI
9	Xu L, Zhang Y, Liu J, Qu J, Hu X, Zhang F, Zheng H, Qu X and Liu Y: TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells. Eur J Cancer. 48:3288–3299. 2012. View Article : Google Scholar : PubMed/NCBI
10	Xu L, Qu X, Li H, Li C, Liu J, Zheng H and Liu Y: Src/caveolin-1-regulated EGFR activation antagonizes TRAIL-induced apoptosis in gastric cancer cells. Oncol Rep. 32:318–324. 2014.PubMed/NCBI
11	Choo MK, Kawasaki N, Singhirunnusorn P, Koizumi K, Sato S, Akira S, Saiki I and Sakurai H: Blockade of transforming growth factor-beta-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade. Mol Cancer Ther. 5:2970–2976. 2006. View Article : Google Scholar : PubMed/NCBI
12	Nishimura M, Shin MS, Singhirunnusorn P, Suzuki S, Kawanishi M, Koizumi K, Saiki I and Sakurai H: TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-{kappa}B-independent survival pathways in tumor necrosis factor alpha signaling. Mol Cell Biol. 29:5529–5539. 2009. View Article : Google Scholar : PubMed/NCBI
13	Wang C, Chen T, Zhang N, Yang M, Li B, Lü X, Cao X and Ling C: Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IkappaBalpha kinase-NFkappaB. J Biol Chem. 284:3804–3813. 2009. View Article : Google Scholar : PubMed/NCBI
14	Refaat A Aminullah, Zhou Y, Kawanishi M, Tomaru R, Abdelhamed S, Shin MS, Koizumi K, Yokoyama S, Saiki I and Sakurai H: Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells. Biochem Biophys Res Commun. 458:856–861. 2015. View Article : Google Scholar : PubMed/NCBI
15	Tong J, Taylor P, Peterman SM, Prakash A and Moran MF: Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041. Mol Cell Proteomics. 8:2131–2144. 2009. View Article : Google Scholar : PubMed/NCBI
16	Refaat A, Zhou Y, Suzuki S, Takasaki I, Koizumi K, Yamaoka S, Tabuchi Y, Saiki I and Sakurai H: Distinct roles of transforming growth factor-beta-activated kinase 1 (TAK1)-c-Rel and interferon regulatory factor 4 (IRF4) pathways in human T cell lymphotropic virus 1-transformed T helper 17 cells producing interleukin-9. J Biol Chem. 286:21092–21099. 2011. View Article : Google Scholar : PubMed/NCBI
17	Lee SJ, Noh HJ, Sung EG, Song IH, Kim JY, Kwon TK and Lee TJ: Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins. Int J Oncol. 38:485–492. 2011. View Article : Google Scholar : PubMed/NCBI
18	Zaidi SF, Refaat A, Zhou Y, Sualeh Muhammad J, Shin MS, Saiki I, Sakurai H and Sugiyama T: Helicobacter pylori induces serine phosphorylation of EGFR via novel TAK1-p38 activation pathway in an HB-EGF-independent manner. Helicobacter. Feb 23–2015. View Article : Google Scholar : PubMed/NCBI
19	Zhou Y, Tanaka T, Sugiyama N, Yokoyama S, Kawasaki Y, Sakuma T, Ishihama Y, Saiki I and Sakurai H: p38-Mediated phosphorylation of Eps15 endocytic adaptor protein. FEBS Lett. 588:131–137. 2014. View Article : Google Scholar : PubMed/NCBI